Pharma BD Deal Intelligence
Sanofi's $784M India vaccine bet spent years in regulatory purgatory, then Sanofi quietly exited entirely in 2024.
Full analysis, sources & comparables →Sanofi-Aventis paid EUR 550M (~$784M) for Shantha — part of CEO Viehbacher's strategy to aggressively grow vaccines in emerging markets, his fourth vaccine…
Sanofi takes control of Shantha through the ShanH subsidiary of Mérieux Alliance, which held the 80% stake — structuring the deal to layer in Mérieux's…
Sanofi-Aventis acquired an 80% controlling stake valuing the firm at $784 M USD; a landmark deal demonstrating that large multinationals recognized the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Controlling stake via ShanH/Mérieux Alliance subsidiary. Indian vaccine maker. Source: Sanofi filings, SEC EDGAR, Nature Biotech.
Sanofi's $784M India vaccine bet spent years in regulatory purgatory, then Sanofi quietly exited entirely in 2024.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi-Aventis / Shantha Biotechnics Limited (this deal) | 2009 | $784M | 34 |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
| Sanofi-Aventis / Merial Limited (Merck's 50% interest) | 2009 | $4.0B | 65 |
| Sanofi-Aventis / Acambis plc | 2008 | $548M | 36 |
| Sanofi-Aventis / Fovea Pharmaceuticals SA | 2009 | $541M | 23 |
| Sanofi-Aventis / BiPar Sciences, Inc. | 2009 | $500M | 8 |
| Sanofi-Aventis / ImmunoGen Inc. | 2005 | $18M | — |
← Browse all deals · How we score deals
More: 2009 deals · Sanofi-Aventis deals